Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection

被引：5
|
作者：
Price, Jennifer C. [1 ]
Seaberg, Eric C. [2 ]
Phair, John P. [3 ]
Witt, Mallory D. [4 ]
Koletar, Susan L. [5 ]
Thio, Chloe L. [6 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Gastroenterol & Hepatol, 513 Parnassus Ave,S-357, San Francisco, CA 94143 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Northwestern Univ, Dept Med, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles Biomed Res Inst,Harbor UCLA, Torrance, CA USA
[5] Ohio State Univ, Dept Med, Div Infect Dis, Columbus, OH 43210 USA
[6] Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 03期
基金：
美国国家卫生研究院;
关键词：
HIV; HBV; HCV; antiviral therapy; liver; hepatitis; APRI; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; MULTICENTER AIDS COHORT; PLATELET RATIO INDEX; FIBROSIS PROGRESSION; MONOINFECTED PATIENTS; COINFECTED PATIENTS; NONINVASIVE INDEX; HUMAN HEPATOCYTES; VIRAL-HEPATITIS;
D O I：
10.1097/QAI.0000000000000981
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
To determine the impact of highly active antiretroviral therapy (HAART) on liver disease, we analyzed changes in the aspartate aminotransferase to platelet ratio index (APRI) pre-and post-HAART initiation among 441 HIV-monoinfected and 53 HIV-viral hepatitis-coinfected men. Before HAART, APRI increased 17% and 34% among the HIV-monoinfected and coinfected men, respectively. With HAART initiation, APRI decreased significantly in men who achieved HIV RNA of <500 copies per milliliter: 16% for HIV-monoinfected and 22% for coinfected men. Decreases in APRI were dependent on HIV suppression. This protective effect of HAART decreased after 2 years, particularly in the HIV-monoinfected men.
引用
收藏
页码：319 / 323
页数：5
相关论文
共 50 条
  • [31] Epidermodysplasia verruciformis in a patient with HIV infection:: no response to highly active antiretroviral therapy
    Carré, D
    Dompmartin, A
    Verneuil, L
    Verdon, R
    Comoz, F
    Le Brun, E
    Freymuth, F
    Leroy, D
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (04) : 296 - 300
  • [32] Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection
    Markert, ML
    Hicks, CB
    Bartlett, JA
    Harmon, JL
    Hale, LP
    Greenberg, ML
    Ferrari, G
    Ottinger, J
    Boeck, A
    Kloster, AL
    McLaughlin, TM
    Bleich, KB
    Ungerleider, RM
    Lyerly, HK
    Wilkinson, WE
    Rousseau, FS
    Heath-Chiozzi, ME
    Leonard, JM
    Haase, AT
    Shaw, GM
    Bucy, RP
    Douek, DC
    Koup, RA
    Haynes, BF
    Bolognesi, DP
    Weinhold, KJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (05) : 403 - 413
  • [33] Management of cytomegalovirus retinitis in HIV infection in the era of highly active antiretroviral therapy
    Timperley, Alexandra
    Taha, Huda
    Das, Satyajit
    INTERNATIONAL JOURNAL OF STD & AIDS, 2015, 26 (10) : 757 - 758
  • [34] Cost-effectiveness of highly active Antiretroviral therapy for HIV infection in Taiwan
    Fang, Chi-Tai
    Chang, Yu-Yin
    Hsu, Hsu-Mei
    Twu, Shiing-Jer
    Chen, Kow-Tong
    Chen, Mao-Yuan
    Huang, Loreen Y. L.
    Hwang, Ling-Shiang
    Wang, Jung-Der
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2007, 106 (08) : 631 - 640
  • [35] Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France
    Lagrange-Xelot, M.
    Porcher, R.
    Sarfati, C.
    de Castro, N.
    Carel, O.
    Magnier, J-D
    Delcey, V.
    Molina, J-M
    HIV MEDICINE, 2008, 9 (02) : 126 - 130
  • [36] Pregnancy and HIV disease progression during the era of highly active Antiretroviral therapy
    Tai, Jennifer H.
    Udoji, Mercy A.
    Barkanic, Gema
    Byrne, Daniel W.
    Rebeiro, Peter F.
    Byram, Beverly R.
    Kheshti, Asghar
    Carter, Justine D.
    Graves, Cornelia R.
    Raffanti, Stephen P.
    Sterling, Timothy R.
    JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (07): : 1044 - 1052
  • [37] Residual HIV-1 disease in the era of highly active antiretroviral therapy
    Pomerantz, RJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21): : 1672 - 1674
  • [38] Peyronie's disease in men with HIV responding to highly active antiretroviral therapy
    Rogers, GD
    French, MA
    HIV MEDICINE, 2004, 5 (03) : 185 - 186
  • [39] An emerging severe leukoencephalopathy: is it due to HIV disease or highly active antiretroviral therapy?
    Rackstraw, S
    Meadway, J
    Bingham, J
    Al-Sarraj, S
    Everall, I
    INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (03) : 205 - 207
  • [40] Cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy
    Jericó, C
    Knobel, H
    Carmona, A
    Sorli, ML
    López-Colomés, JL
    Pedro-Botet, J
    MEDICINA CLINICA, 2004, 122 (08): : 298 - 300
12345